Sareum Holdings PLC Sareum Announces Two New Granted Patents (8021D)
26 6월 2023 - 3:00PM
UK Regulatory
TIDMSAR
RNS Number : 8021D
Sareum Holdings PLC
26 June 2023
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum announces two new granted patents, including first patent
specifically for SDC-1801
Cambridge, UK , 26 June 2023 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next generation
kinase inhibitors for autoimmune disease and cancer, today
announces that the first patent specifically relating to SDC-1801,
its lead TYK2/JAK1 kinase inhibitor, has been granted in China.
Further, a patent has been formally granted for SDC-1802 and
several analogues in the United States, extending the scope of
protection beyond immuno-oncology.
Dr John Reader, Sareum's Chief Scientific Officer, commented:
"We're delighted to have the first patent granted for SDC-1801, our
lead development programme which recently advanced into a Phase 1a
clinical trial in Australia. We look forward to being able to
strengthen our intellectual property around this asset in other
territories in due course."
"Separately, we are really pleased to have extended the scope of
patent protection for SDC-1802 in the US. Although oncology remains
the primary focus of this asset, this bulwarks our intellectual
property position and gives us optionality to explore opportunities
in other therapeutic areas."
SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as
a potential new therapeutic for a range of autoimmune diseases with
an initial focus on psoriasis, an autoimmune dermatological
condition affecting more than 60 million adults worldwide, with a
market size for potential treatments estimated to be worth more
than US$30 billion. Sareum recently announced that it has begun
dosing healthy subjects in a Phase 1a clinical trial for SDC-1801,
in Australia.
The China National Intellectual Property Administration (CNIPA)
has officially issued patent number CN113056456B, safeguarding
SDC-1801 and medical applications of it in treating inflammatory or
immune disorders. This is the first patent grant issued to Sareum
for SDC-1801 in any territory. Patent applications in Europe
(EP3864009), the US (US2021387981) and other territories are still
under review.
SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer
immunotherapy. Sareum continues to work on the translational
studies needed to support the development of SDC-1802, defining the
optimal cancer application prior to completing toxicology and
manufacturing studies.
The United States Patent and Trademark Office (USPTO) has
formally granted patent number US 11,673,870 B2 specifically
covering the treatment of autoimmune disorders with SDC-1802 and
several analogues. While Sareum has previously secured
international patents providing comprehensive protection for the
compound SDC-1802, this patent extends its scope in the US beyond
immuno-oncology.
Further information on our patents can be found on our website
at: https://sareum.com/patents/
-Ends-
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
Lauren Williams, Head of Investor Relations ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman 020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel / Oliver Duckworth 020 7418 8900
Hybridan LLP (Joint Corporate Broker)
Claire Noyce 020 3764 2341
Consilium Strategic Communications (Financial
PR)
Jessica Hodgson / Davide Salvi / Stella
Lempidaki 020 3709 5700
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology
company developing next generation kinase inhibitors for autoimmune
disease and cancer.
The Company is focused on developing next generation small
molecules which modify the activity of the JAK kinase family and
have best-in-class potential. Its lead candidate, SDC-1801,
simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential
treatment for a range of autoimmune diseases and has entered Phase
1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1
inhibitor which it originally developed in collaboration with
several Cancer Research UK-related organisations. SRA737 has shown
promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a
potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on
the AIM market of the London Stock Exchange, trading under the
ticker SAR. For further information, please visit the Company's
website at www.sareum.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAKKDADPDEFA
(END) Dow Jones Newswires
June 26, 2023 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Sareum (LSE:SAR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024